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Abstract
Background: The purpose of the study was to investigate the effects of the pregnane X receptor (PXR)*1B
polymorphisms on CYP3A4 enzyme activity and postoperative fentanyl consumption in Chinese patients
undergoing gynecological surgery.
Methods: A total of 287 females of Han ethnicity, aged 20 to 50 years old, ASA I or II, scheduled to abdominal total
hysterectomy or myomectomy under general anesthesia were enrolled. The analgesic model used was fentanyl
consumption via patient-controlled intravenous analgesia (PCIA) in the post-operative period. Additionally, pain was
assessed using a visual analog score (VAS). Pain scores, occurrence of adverse reactions and consumption of fentanyl
were recorded during the 24 h postoperative period. The enzyme activity of CYP3A4 was evaluated by measuring the
plasma ratio of 1′-hydroxymidazolam to midazolam 1 h after intravenous administration of 0.1 mg/kg midazolam. PXR
genotyping was performed by direct DNA sequencing and the PXR*1B haplotype was analyzed via PHASE V.2.1 software.
Results: The polymorphism frequency of PXR11156A> C/11193 T > C and 8055C > T were 49.6 and 49.3%, and the rate of
PXR*1B haplotype was 48.8% in our study. None of the pain scores, consumption of fentanyl 24 h post-operatively or
enzyme activity of CYP3A4, showed differences among different genotypes.
Conclusions: PXR11156A > C, PXR11193T > C, PXR8055C > T or the PXR*1B haplotype do not appear to be important factors
contributing to CYP3A4 activity and interindividual variations in postoperative fentanyl consumption in Han female
patients undergoing gynecological surgery.
Trial registration: The DNA samples were obtained since 2007 to 2010 year in our hospital, there was no registration at
that time. So this section is not applicable to our research.
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Background
Fentanyl, an intravenous μ-opioid receptor agonist, is
widely used for postoperative analgesia. However, the an-
algesic effect of fentanyl demonstrates significant inter-
individual variation [1]. These variations in response can
lead to inadequate pain relief and may affect the incidence
of adverse events such as respiratory depression and
muscle stiffness [2, 3]. Dolin et al. [4] reported that ap-
proximately 30–40% of patients using postoperative
patient-controlled analgesia (PCA) reported moderate to
severe pain and 10% reported severe pain.
Part of the variable response to pain medications may
be attributed to genetic factors [5].
Fentanyl is mainly metabolized by cytochrome P450
family 3 subfamily A member 4, (CYP3A4) [6–8], which is
the most abundant metabolic enzyme in liver. The level of
expression and activity of CYP3A4 showed a 10–100-fold
inter-individual difference [9–11]. Prior studies have
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indicated that genetic factors could significantly affect the
pharmacokinetics and pharmacodynamics of drugs by
altering the expression of drug-metabolizing enzymes or
their activities [12, 13].
PXR is a nuclear receptor that serves a primary role in
the up-regulation of proteins and enzymes in response
to endogenous and exogenous substances and it was
found to be a key regulator of CYP3A4 [11, 12]. Poly-
morphic variations of the PXR gene, such as the haplo-
type of PXR*1B has been confirmed to contribute to
both of the mRNA level and the protein content of
CYP3A4 [13, 14]. The PXR*1B haplotype is composed of
PXR 11193 T > C and PXR 8055C > T, PXR 11156A > C
is in complete linkage with PXR 11193 T > C and is simi-
lar to it [14, 15]. PXR*1B has three haplotypes: non-
PXR*1B haplotype (wild homozygotes of the three
genes), PXR*1B haplotype (heterozygotes of the three
genes) and PXR*1B/*1B (mutant homozygotes of the
three genes). However, it is still elusive if PXR*1B haplo-
type has sufficient effect on the catalytic activity of the
CYP3A4 enzyme, and subsequently alter the analgesic
effect of fentanyl for postoperative pain control.
Methods
Some of methods were referred to the study done by W
Zhang et al. [6] as the following:
Subjects
A total of 287 females, of self-reported Han ethnicity,
aged20 to 50 years old, with a physical status of American
Society of Anesthesiologists (ASA) I or II and scheduled for
abdominal total hysterectomy or myomectomy under gen-
eral anesthesia were screened at the First Affiliated Hospital
of Zhengzhou University. All subjects and genetic material
obtained during the period of 2007 and 2010 were a subset
of a larger group of 330 patients collected for medical stud-
ies. All samples that had relative full information and a us-
able blood sample were included in this study. The study
protocol was previously approved by the Institutional Ethics
Committee of Zhengzhou University and every patient pro-
vided signed informed consent. Participants with a history
of psychiatric diseases, cardiovascular diseases, hepatic and
renal dysfunction, alcohol or drug abuse, diabetes or
chronic analgesic use were excluded. Patients were also
questioned about diet and medication intake 2 weeks prior
to their surgery and were excluded if they reported con-
suming any drugs or food that are known to inhibit the
expression level or activity of the CYP3A4 enzyme (clari-
thromycin, erythromycin, grapefruit juice etc.) [6]. All pa-
tients were operated on by the same group of 4 surgeons.
Anesthetic procedure
Patients were not given any premedication and standard
monitors were used. During the induction of anesthesia,
midazolam (0.1 mg/kg), propofol (0.5 mg/kg) and remi-
fentanil (2 μg/kg) were utilized. Succinylcholine (1 mg/
kg) provided muscle relaxation for intubation. During
the surgical procedure, propofol 100–150 mcg/kg/min
and remifentanil 0.1–0.2 μg/kg/min were continuously
infused. To maintain adequate muscle relaxation, an ini-
tial dose of atracurium (0.6 mg/kg) was given immedi-
ately after tracheal intubation, and intermittent doses
(0.1–0.2 mg/kg) were utilized during the case. All patients
were intubated and mechanically ventilated with a target
end-tidal CO2 of 35–40 mmHg. Fentanyl (1 μg/kg), as a
loading dose, was infused intravenously approximately
30 min prior to the completion of surgery. All anesthetics
were stopped at the end of surgery. Atropine (0.5 mg) and
neostigmine (1 mg) were used to reverse muscle relax-
ation in all patients. Patients were extubated after ad-
equate recovery as was judged by the anesthesiologist.
Assessment of postoperative analgesia
After extubation, all patients were assessed in the oper-
ating room using a visual analog scale (VAS, 0 = no pain,
10 = unbearable pain). Fentanyl 20 μg was given to pa-
tients whose VAS was over 3 and was redosed every 5 mi-
nutes until the VAS score was less than 3; at which time a
PCA with fentanyl was immediately begun. The dose of
fentanyl, VAS score, the occurrence of adverse reactions
after surgery and 24 h after surgery were recorded.
Fig. 1 The electrophoregram of PXR11156A > C and PXR11193T > C.
Peripheral venous blood samples were taken from all patients. Genomic
DNA was extracted using a conventional phenol-chloroform procedure.
Genotyping of PXR11156A > C, PXR11193T > C allele was conducted by
polymerase chain reaction (PCR), following with direct sequencing.
PXR*1B haplotype was genotyped by PHASE V.2.1 software. Figure 1
showed the 258 bp band of the PCR amplification product which
contained PXR11193T > C. The DM500 marker, which contains the bands
of 50 bp, 100 bp, 150 bp, 200 bp, 300 bp, 400 bp and 500 bp was used
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The PCA pump contained a total of fentanyl 1.0 mg,
droperidol 5 mg and saline to reach a total volume of
100 ml, with a final concentration of 10 μg/ml of fen-
tanyl. The pump was set with a background rate of
0.5 ml per hour (a background infusion of 5 μg fentanyl/h).
Doses were set at 2 ml, with a lockout time of 5 min, allow-
ing a maximum dose of 145 μg per hour. If the VAS score
remained above 3, with a maximum dose of fentanyl, other
analgesics would be given and the patient was be excluded
from the trial.
Genotyping for PXR polymorphisms
Peripheral venous blood samples (2 ml) were obtained
from all patients enrolled. Genomic DNA was extracted
using a conventional phenol-chloroform procedure. Geno-
typing of PXR11156A > C, PXR11193T > C and 8055C > T
was conducted by polymerase chain reaction (PCR) and
direct sequencing. The PXR*1B haplotype was genotyped
by PHASE V.2.1 software. The results, including agarose
gel electrophoresis and DNA sequencing, are shown in
Figs. 1, 2, 3 and 4.
Genotyping of the PXR11156A > C and PXR11193T >
C polymorphisms was previously described by Wang XD
et al. [15]. Genotyping of the PXR8055C > T polymorph-
ism was identified by the following process, a 216-bp
fragment, including the single nucleotide polymorphism
(SNP) 8055C > T, was created. The forward and reverse
primers used for amplification were PXR8055C > T (for-
ward: 5′-GGCAGGAAGATGGAATGG-3′ and reverse:
5′-GGGAGAAGAGGGAGATGG-3′). The 50 μl reac-
tion mixture included 25 μl of 2 × Taq PCR Master Mix
(Applied Biosystems), 1 μl of each of primers, 0.5 μl of
cDNA template, and 22.5 μl of deionized water (diH2O).
The amplification of PXR8055C > T was performed by the
following process: 3-min initial denaturation at 94 °C,
denaturation at 94 °C for 30s, anneal at 57 °C for
30s, elongation at 72 °C for 30s, followed by 30 cycles,
then extended at 72 °C for 5 min. The amplification
products were kept at 4 °C and identified by the agarose
gel electrophoresis. Genotyping of SNPs was performed
by direct sequencing. For each polymorphism of PXR
(PXR11156A > C, PXR11193T > C and 8055 C > T), pa-
tients were assigned to three groups according to the
genotypes: wild homozygotes, heterozygotes group and
mutant homozygotes. Patients were also divided into three
haplotypes analyzed by PHASE V.2.1 software: non-
PXR*1B haplotype, PXR*1B haplotype and PXR*1B/*1B
haplotype as described in the background (Table 1).
Evaluation of CYP3A4 activity
The CYP3A4 activity was determined by the plasma ra-
tio of 1′-hydroxymidazolam (1′-MDZ) to midazolam
PXR11193TT PXR11193TC PXR11193CC
Fig. 2 The DNA sequence of PXR11193T > C. Genomic DNA was extracted using a conventional phenol-chloroform procedure. Genotyping of
PXR11193T > C allele was conducted by polymerase chain reaction (PCR), direct sequencing. PXR*1B haplotype was genotyped by PHASE V.2.1
software. Two T bases were showed in the PXR11193T > C wild homozygotes. One T base and one C base were showed in the PXR11193T > C
heterozygotes. Two C bases were showed in the mutant homozygotes
Fig. 3 The electrophoresis of PXR8055C > T. Genomic DNA was
extracted using a conventional phenol-chloroform procedure.
Genotyping of PXR8055C > T allele was conducted by polymerase
chain reaction (PCR), following with direct sequencing. PXR*1B
haplotype was genotyped by PHASE V.2.1 software. Figure 3 showed
the 216 bp band of the PCR amplification product which contained
PXR8055C > T. The DM500 marker, which contains the bands of
50 bp, 100 bp, 150 bp, 200 bp, 300 bp, 400 bp and 500 bp was used
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(MDZ), at 1 h after the intravenous injection of
midazolam 0.1 mg/kg for induction. Liquid chroma-
tography mass spectrometry (LC/MS) was used to
measure the level of 1′- MDZ and MDZ as described
by Kanazawa et al. [16].
Statistical analysis
SPSS 17.0 software (SPSS Inc., Chicago, Illinois, USA)
was used for statistical analyses. Values were reported
as mean SD. The Chi-square test was used to verify
Hardy-Weinberg equilibrium. Data for the fentanyl con-
sumption were compared using one-way analysis of vari-
ance with post hoc Bonferroni correction. Between-group
comparisons of the VAS score were performed with the
Mann–Whitney U test. Multiple comparisons were per-
formed before and after being adjusted for age, weight and
the intraoperative remifentanyl dosing. The incidences of
adverse effects were analyzed using the Chi-square test or
Fisher exact test. Power analysis of the post-operative fen-
tanyl consumption was performed with the NCSS PASS
2008 (NCSS Inc., Kaysville, Utah, USA). A P-value of less
than 0.05 was set to indicate statistical significance.
Results
All 287 women who were taken from the larger cohort
were included in the final pain analysis final. The fre-
quency of the PXR11193T > C allele was 49.6%; the fre-
quency of PXR8055C > T allele was 49.3%; the frequency
of PXR*1B haplotype was 48.8%. Allele frequencies were
in Hardy-Weinberg equilibrium (P > 0.05).
Although patients received an intravenous infusion of
fentanyl (1 μg/kg) approximately 30 min prior to the com-
pletion surgery, the VAS pain score at the end of surgery
was a mean of 6.1 ± 1.2. The pain score At 24 h after sur-
gery was 2.2 ± 0.7 on average. No patient required rescue
management for inadequate pain control. The mean fen-
tanyl consumption was 452 μg ± 86 μg in the 24 h period
after surgery. The incidence of postoperative nausea and
vomiting was 20.8%. The incidence of mild sedation and
dizziness in our study was 6.9 and 5.6%, respectively.
There was no difference in demographics, VAS pain
scores at the end of surgery or at 24 h postoperatively
between groups (P > 0.05). There were no statistically
significant differences in PCA fentanyl consumption for
the 24 h period after surgery between groups (P > 0.05).
Additionally, the enzyme activity of CYP3A4 showed no
significant variation relative to genotype (Tables 2 and 3).
There were no statistical differences in the incidence of
the side effects between PXR haplotypes (P > 0.05)
Discussion
PXR is a key transcription activating factor for the expres-
sion of the CYP3A4 gene [13, 14]. A model of transgenic
mice, produced in 2000, demonstrated that PXR plays an
important role in the expression of CYP3A4 [13]. The
PXR*1B haplotype (PXR1156A >C, PXR11193T > C and
PXR8055C > T) has been shown previously to effect the
PXR8055CC PXR8055CT PXR8055TT
Fig. 4 The DNA sequence of PXR8055C > T. Genomic DNA was extracted using a conventional phenol-chloroform procedure. Genotyping of
PXR8055C > T allele was conducted by polymerase chain reaction (PCR), direct sequencing. PXR*1B haplotype was genotyped by PHASE V.2.1
software. Two C bases were showed in the PXR8055C > T wild homozygotes. One T base and one T base were showed in the PXR8055C > T
heterozygotes. Two T bases were showed in the mutant homozygotes
Table 1 Composition of PXR polymorphisms and PXR*1B
haplotypes
Non-PXR*1B (n = 73) PXR*1B (n = 140) PXR*1B/*1B (n = 70)
1156 A > C AA (73) AC (140) CC (75)
11193 T > C TT (75) TC (141) CC (71)
8055 C > T CC (74) CT (144) TT (70)
Data are expressed as numbers
Table 2 General information for PXR*1B haplotypes
Non-PXR*1B PXR*1B PXR*1B/*1B P value
Age (years) 41 ± 5 40 ± 6 42 ± 4 0.100
BMI (kg/m2) 21.8 ± 2.0 22.1 ± 2.1 23.0 ± 2.3 0.666
Total hysterectomy 50 92 39 0.832
Myomectomy 22 48 21 0.224
Operation time (min) 90 ± 14 88 ± 17 95 ± 11 0.804
Propofol (mg) 560 ± 89 550 ± 90 570 ± 91 0.770
Remifentanil (μg) 921 ± 130 914 ± 106 945 ± 137 0.449
Data are expressed as numbers or mean ± SD. Drug doses are totals
Yuan et al. BMC Medical Genetics  (2016) 17:87 Page 4 of 6
metabolic parameters of doxorubicin in patients with
breast cancer [17]. Gender has been reported to influence
the enzyme activity of CYP3A4 [18], however, since this
study was limited to gynecology patients, gender variation
was not an issue.
Midazolam was used as a probe drug for the CYP3A4
enzyme and is metabolized to 1′-OH midazolam by
CYP3A4 enzyme. The metabolic breakdown of midazo-
lam is primarily influenced by the activity of CYP3A4,
not blood flow to the liver [19]. However, we found no
significant differences in metabolism based on genotype.
We noted that occurrence rate of PXR*1B was 48.8%
and appeared to be in Hardy-Weinberg equilibrium.
Our study demonstrated that the PXR*1B haplotype
did not influence the analgesic effects of fentanyl post-
operatively and therefore does not appear to be a main
determining factor for variations in fentanyl use.
In Asian patients with breast cancer, PXR*1B haplotype
affected the PXR mRNA level. Patients with the PXR*1B
haplotype showed a lower PXR mRNA level compared
with the patients with non- PXR*1B haplotype. PXR*1B-
bearing liver tissues were associated with significantly lower
expression of CYP3A4 compared with non- PXR*1B-bear-
ing liver tissues. Furthermore, PXR*1B haplotype had an re-
ducing-effect on the elimination rate of doxorubicin
[19, 20]. In the present research, difference of the fentanyl
consumption during the first 24 h postoperatively among
the PXR*1B haplotypes was not found. However, a de-
creasing trend of the fentanyl consumption during the first
24 h postoperatively among the PXR*1B haplotypes was
found. That was, fentanyl consumption was much lower
in the patients containing PXR*1B haplotype. It might due
to the limitation of our research sample size, statistical sig-
nificance could not be obtained. Since it is impractical to
obtaine liver samples from the subjects. The CYP3A4 pro-
tein levels were not be able to be detected, either. On the
other hand, doxorubicin and fentanyl are also substrates
of P-glycoprotein encoded by ABCB1 gene. Since P-
glycoprotein is also affected by the nuclear receptor-PXR
at transcriptional level [21], we speculate that the genetic
variations of the PXR*1B haplotype have a more significant
effect on ABCB1 than CYP3A4.
The study only evaluated the effects of the PXR*1B
haplotype on the analgesic effect of fentanyl. The
determination of the fentanyl metabolism in vivo may be
impacted by not only the protein expression, but also
the CYP3A4 activity, and other factors such as CYP3A5
enzyme and other drug interactions etc. Due to study
limitations we were unable to actually determine the
level of CYP3A4 protein expression in the hepatocytes
of subjects. In the future a study that extracts micro-
somes from hepatic cells and assesses the protein ex-
pression and the activity of CYP3A4 enzyme in vitro
may avoid any confounding factors.
There was a limitation to our research. 330 samples
were collected during 2007 and 2010. Although we al-
most genotyped the entire DNA samples, not every sam-
ple had the whole data we need in this research.
Especially for the CYP3A enzyme activity, we only got
95 samples’ data. The statistical power for the fentanyl
consumption was 0.736 and it was low for the CYP3A
enzyme activity.
Conclusions
In summary, we investigated the effects of the polymor-
phisms of PXR*1B on intravenous postoperative anal-
gesia with fentanyl in patients undergoing selective
abdominal total hysterectomy or myomectomy under
general anesthesia. Our results failed to found significant
effects contributed by the polymorphisms of PXR*1B.
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Table 3 Effect of PXR*1B haplotypes on postoperative analgesia
Non-PXR*1B PXR*1B PXR*1B/*1B P value
Initial postoperative VAS scores 6.1 ± 1.3 6.2 ± 1.1 5.9 ± 1.0 0.414
Mean VAS scores during first 24 h 2.1 ± 0.7 2.3 ± 0.8 2.2 ± 0.8 0.601
Fentanyl consumption during first 24 h (μg) 468 ± 83 453 ± 85 435 ± 87 0.062
bCYP3A activity (1′-OHMDZ:MDZ) 0.40 ± 0.12 0.39 ± 0.14 0.40 ± 0.11 0.885
Data are expressed as mean ± SD. Statistical significance was set at P < 0.05. P values are adjusted by age, sex, weight, remifentanyl dose during the operation,
and type of surgery. bCYP3A4 activity (n = 95)
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